Computational studies of 1-hydrazinophthalazine (hydralazine) as an antineoplasic agent.: Docking studies on methyltransferase

被引：24

作者：

Angeles, E

Vázquez-Valadéz, VH

Vázquez-Valadéz, O

Velázquez-Sánchez, AM

Ramírez, A

Martínez, L

Díaz-Barriga, S

Romero-Rojas, A

Cabrera, G

López-Castañares, R

Dueñas-González, A

机构：

[1] Univ Nacl Autonoma Mexico, FESC, Lab Quim Med, Mexico City 54740, DF, Mexico

[2] Univ Nacl Autonoma Mexico, IIB, Unidad Invest Biomed Canc, Mexico City, DF, Mexico

来源：

LETTERS IN DRUG DESIGN & DISCOVERY | 2005年 / 2卷 / 04期

关键词：

docking; hydralazine; DNA methyltransferase; DNA methylation inhibitor; tumor suppressor gene;

D O I：

10.2174/1570180054038413

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Hydralazine is a drug used as anti-hypertensive, and recently reported to be a DNA methylation inhibitor able to demethylate and reactivate the expression of tumor suppressor genes in cancer. The aim of the present study was to explore the potential mechanism by which hydralazine inhibits DNA methylation. For this purpose, we assessed the structural and electronic properties between 1-hydrazinophthalazine (hydralazine) and a putative ligand methyltransferase.

引用

页码：282 / 286

页数：5

共 24 条

[1] REQUIREMENT OF RIBONUCLEOTIDE REDUCTASE FOR COBAMIDE COENZYME A PRODUCT OF RIBOSOMAL ACTIVITY [J].